Team:Amsterdam/practices/overview
From 2012.igem.org
(Difference between revisions)
Mmendeville (Talk | contribs) |
|||
Line 9: | Line 9: | ||
Synthetic biology (SB) is a quickly developing branch of biotechnology with many promising benefits for human society. As a consequence of this development, awareness among the public increases. Past debates on genetic engineering suggest that in order to omit exaggerated hopes and fears, scientists should adopt an open approach towards the public. The whole concept of involving the public has only been around for the past three decades; it was in the early 1980s that scientists and policy makers began to acknowledge that public engagement could be beneficial to both science and society. This is particularly the case with developments in the field of biotechnology because they come with both high expectations for society as well as concerns about risks, privacy, sustainability and commercialization. | Synthetic biology (SB) is a quickly developing branch of biotechnology with many promising benefits for human society. As a consequence of this development, awareness among the public increases. Past debates on genetic engineering suggest that in order to omit exaggerated hopes and fears, scientists should adopt an open approach towards the public. The whole concept of involving the public has only been around for the past three decades; it was in the early 1980s that scientists and policy makers began to acknowledge that public engagement could be beneficial to both science and society. This is particularly the case with developments in the field of biotechnology because they come with both high expectations for society as well as concerns about risks, privacy, sustainability and commercialization. | ||
- | Also, involvement of relevant stakeholders is required to enable a flexible way to deal with upcoming problems. Two approaches that have this involvement of stakeholders in the shaping and execution of research and development in common are Constructive Technology Assessment (CTA) and Midstream Modulation (MM). The main difference between these two strategies is that in MM societal and contextual issues are denoted via a social scientist, whether in CTA the researchers themselves are more directly involving stakeholders. | + | Also, involvement of relevant stakeholders is required to enable a flexible way to deal with upcoming problems. Two approaches that have this involvement of stakeholders in the shaping and execution of research and development in common are Constructive Technology Assessment (CTA) and Midstream Modulation (MM) [[https://2012.igem.org/Team:Amsterdam/practices/methods#Key_Concepts (See here)]]. The main difference between these two strategies is that in MM societal and contextual issues are denoted via a social scientist, whether in CTA the researchers themselves are more directly involving stakeholders. |
Based on these theories, we designed a new approach in human practices specifically for iGEM projects, which can be adopted by each future iGEM team. In practice, this approach embraces the involvement of experts from various relevant disciplines to share their knowledge and opinions on the technical, safety, ethical, social and legal issues early in the developmental phase of an iGEM project. This approach will help you guide and develop your project into a product that will have maximal positive impact and will pass through minimal legislative and societal hindrance. | Based on these theories, we designed a new approach in human practices specifically for iGEM projects, which can be adopted by each future iGEM team. In practice, this approach embraces the involvement of experts from various relevant disciplines to share their knowledge and opinions on the technical, safety, ethical, social and legal issues early in the developmental phase of an iGEM project. This approach will help you guide and develop your project into a product that will have maximal positive impact and will pass through minimal legislative and societal hindrance. |
Revision as of 01:25, 27 September 2012